Autoimmune & Rheumatology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

This Phase 3 trial is exploring baricitinib, a pill taken by mouth, as a treatment for polymyalgia rheumatica (PMR), a condition that causes painful stiffness and inflammation in older adults. Researchers want to see if using baricitinib with corticosteroids works better than corticosteroids alone. For patients, this could mean fewer side effects from steroids and better control of symptoms, improving daily life. The study is recruiting 140 patients in France.

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

This Phase 3 study is testing the safety and how the body processes bimekizumab, a new antibody treatment, in children with certain types of juvenile arthritis. These conditions cause joint pain and swelling in young people. If successful, this treatment might better target inflammation and provide a new option for children aged 2 to under 18 years. The trial is currently enrolling participants across several countries.

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

This Phase 4 trial looks at adding tirzepatide to an existing arthritis medication called ixekizumab for adults who have psoriatic arthritis and are overweight or obese. The goal is to see if this combination helps improve joint health and reduces problems related to weight. This could offer a new approach to managing both arthritis and weight-related complications. The study is recruiting in the United States and Puerto Rico, lasting up to 12 months.

Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS

Researchers are studying abatacept, a drug that changes how the immune system works, in people with early-stage polymyalgia rheumatica. This Phase 3 trial aims to see if abatacept can reduce the need for steroids, which often cause side effects. The study, involving 34 patients in France, focuses on easing symptoms and lowering steroid use to improve patients’ quality of life.

Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration

This Phase 3 trial compares starting febuxostat treatment immediately versus waiting in people with recent gout attacks. Gout causes painful joint inflammation, and early treatment may help control symptoms faster and avoid long-term joint damage. The study is recruiting adults in France, aiming to find the best timing for treatment to benefit patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.